Clonal circulating tumor cell mobilization following chimeric antigen receptor T-cell therapy in metastatic castration-resistant prostate cancer

Background

Metastatic castration-resistant prostate cancer (mCRPC) is an aggressive, treatment-refractory stage of disease with limited treatment options and poor prognosis. Chimeric antigen receptor (CAR)-T cell therapy has demonstrated success in hematological malignancies. However, responses in solid tumors remain variable, underscoring the need for improved real-time monitoring of tumor biology and therapeutic response.